Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could predict bleeding risk in cancer patients

NCT ID NCT07653672

Knowledge-focused Sponsor: Centre Hospitalier Annecy Genevois Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to create a score that uses a special blood test to predict bleeding risk in people with blood cancers and very low platelet counts. Researchers will take an extra blood sample from 410 participants and analyze it with viscoelastometric tests. The goal is to identify who is truly at risk of bleeding, so platelet transfusions can be given only when needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that helps doctors predict which patients are at risk of bleeding, allowing more targeted use of platelet transfusions.
What could go wrong
This is an early exploratory study with only 410 participants at one hospital. The score may not work as well in other settings or patients, and it does not test any new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 410 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The patients included will be selected from the entire cohort of patients with haematological malignancies: * those admitted to the haematology day unit for treatment or assessment, * or patients admitted to the haematology inpatient ward, * or patients being monitored in the haematology outpatient clinic.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients; * Who have been informed about the study and have freely given their informed consent to participate in the study; * With a malignant haematological disorder or bone marrow failure, whether treated or untreated and at any stage of treatment; * With central thrombocytopenia strictly below 20 G/L in a blood sample taken less than 72 hours ago and not having received a transfusion since; * Admitted to a haematology day unit or inpatient ward, or being followed up at a haematology outpatient clinic; * With or without active bleeding; * Affiliated with or covered by a social security scheme. Exclusion Criteria: * Patients who have received at least one of the following treatments: * Antiplatelet agents within 7 days prior to enrolment, * Vitamin K antagonists within 7 days prior to enrolment, * Direct oral anticoagulants within 72 hours prior to enrolment, * Low molecular weight heparin within 24 hours prior to inclusion, * Unfractionated heparin within 6 hours prior to inclusion, * Bruton's tyrosine kinase inhibitor (ibrutinib, zanubrutinib or acalabrutinib) within 72 hours prior to inclusion; * Patients with a history of thrombopathy; * Patients with a history of haemostatic disorders carrying a risk of haemorrhage or thrombosis; * Thrombocytopenia associated with immune thrombocytopenic purpura or disseminated intravascular coagulation; * Patients already enrolled in the study; * Pregnant or breastfeeding women; * Patients under guardianship or curatorship; * Patients who do not understand French; * Patients under judicial protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone marrow failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone marrow failure syndrome hematologic disorder hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Hemorrhage thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Haemorrhage Hematologic malignancies Platelet transfusion Thrombocytopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.